SEC INSIDER TRANSACTIONS

Edwards Lifesciences Corp (EW) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

EW · Edwards Lifesciences Corp

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 28 filings · fetched 2026-11-13T17:39:21Z

Recent reported activity

0purchase rows on this page

10sale rows on this page

58matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-11-10Filed 2026-11-10	Lippis Daniel J.Officer · CVP, TAVR Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References:	M Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative	619D	0	Direct	Form 4 ↗0001225208-26-008802
2026-11-10Filed 2026-11-10	Lippis Daniel J.Officer · CVP, TAVR Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1	S Sale (market/private)Common Stock · Non-derivative	619D	104.25	Direct	Form 4 ↗0001225208-26-008802
2026-11-10Filed 2026-11-10	Lippis Daniel J.Officer · CVP, TAVR Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1	M Exercise / conversionCommon Stock · Non-derivative	619A	72.68	Direct	Form 4 ↗0001225208-26-008802
2026-11-09Filed 2026-11-09	BOBO DONALD E JROfficer · CVP,Strategy/Corp Development Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 12, 2026. F2 This transaction was executed in multiple trades at prices ranging from $103.00 to $103.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References:	M Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative	48,900D	0	Direct	Form 4 ↗0001225208-26-008779
2026-11-09Filed 2026-11-09	BOBO DONALD E JROfficer · CVP,Strategy/Corp Development Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 12, 2026. F2 This transaction was executed in multiple trades at prices ranging from $103.00 to $103.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	48,900D	103.0534	Direct	Form 4 ↗0001225208-26-008779
2026-11-09Filed 2026-11-09	BOBO DONALD E JROfficer · CVP,Strategy/Corp Development Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 12, 2026. F2 This transaction was executed in multiple trades at prices ranging from $103.00 to $103.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1	M Exercise / conversionCommon Stock · Non-derivative	48,900A	72.68	Direct	Form 4 ↗0001225208-26-008779
2026-11-09Filed 2026-11-09	Zovighian Bernard JDirector · Officer · CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 28, 2026. F2 This transaction was executed in multiple trades at prices ranging from $103.18 to $103.66 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $102.17 to $103.16 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F4 These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F4	M Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative	23,100D	0	Direct	Form 4 ↗0001225208-26-008780
2026-11-09Filed 2026-11-09	Zovighian Bernard JDirector · Officer · CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 28, 2026. F2 This transaction was executed in multiple trades at prices ranging from $103.18 to $103.66 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $102.17 to $103.16 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F4 These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1, F3	S Sale (market/private)Common Stock · Non-derivative	13,916D	102.7803	Direct	Form 4 ↗0001225208-26-008780
2026-11-09Filed 2026-11-09	Zovighian Bernard JDirector · Officer · CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 28, 2026. F2 This transaction was executed in multiple trades at prices ranging from $103.18 to $103.66 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $102.17 to $103.16 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F4 These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	9,184D	103.3851	Direct	Form 4 ↗0001225208-26-008780
2026-11-09Filed 2026-11-09	Zovighian Bernard JDirector · Officer · CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 28, 2026. F2 This transaction was executed in multiple trades at prices ranging from $103.18 to $103.66 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $102.17 to $103.16 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F4 These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1	M Exercise / conversionCommon Stock · Non-derivative	23,100A	72.68	Direct	Form 4 ↗0001225208-26-008780
2026-10-08Filed 2026-10-08	Lippis Daniel J.Officer · CVP, TAVR Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References:	M Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative	619D	0	Direct	Form 4 ↗0001225208-26-008338
2026-10-08Filed 2026-10-08	Lippis Daniel J.Officer · CVP, TAVR Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1	S Sale (market/private)Common Stock · Non-derivative	619D	85.65	Direct	Form 4 ↗0001225208-26-008338
2026-10-08Filed 2026-10-08	Lippis Daniel J.Officer · CVP, TAVR Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1	M Exercise / conversionCommon Stock · Non-derivative	619A	72.68	Direct	Form 4 ↗0001225208-26-008338
2026-09-14Filed 2026-09-14	Markowitz WayneOfficer · CVP, JAPAC Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e). This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1	F WithholdingCommon Stock · Non-derivative	568D	84.37	Direct	Form 4 ↗0001225208-26-007812
2026-09-13Filed 2026-09-14	Dahl Andrew M.Officer · SVP, Corporate Controller Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e). This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1	F WithholdingCommon Stock · Non-derivative	253D	84.37	Direct	Form 4 ↗0001225208-26-007811
2026-09-11Filed 2026-09-14	Markowitz WayneOfficer · CVP, JAPAC Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e). This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1	F WithholdingCommon Stock · Non-derivative	355D	86.77	Direct	Form 4 ↗0001225208-26-007812
2026-09-11Filed 2026-09-11	Chopra DaveenOfficer · CVP, TMTT, Surgical & IHFM Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e). This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1	F WithholdingCommon Stock · Non-derivative	398D	86.77	Direct	Form 4 ↗0001225208-26-007775
2026-09-11Filed 2026-09-11	Lippis Daniel J.Officer · CVP, TAVR Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References:	M Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative	619D	0	Direct	Form 4 ↗0001225208-26-007774
2026-09-11Filed 2026-09-11	Lippis Daniel J.Officer · CVP, TAVR Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1	S Sale (market/private)Common Stock · Non-derivative	619D	87.51	Direct	Form 4 ↗0001225208-26-007774
2026-09-11Filed 2026-09-11	Lippis Daniel J.Officer · CVP, TAVR Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1	M Exercise / conversionCommon Stock · Non-derivative	619A	72.68	Direct	Form 4 ↗0001225208-26-007774
2026-08-31Filed 2026-08-31	Dahl Andrew M.Officer · SVP, Corporate Controller Filing context Reported filing row; may be amended. Do not sum filings blindly. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan. References:	S Sale (market/private)Common Stock · Non-derivative	544D	91.055	Direct	Form 4 ↗0001225208-26-007408
2026-08-28Filed 2026-08-28	Bruls AnnetteOfficer · CVP, EMEACLA Filing context Reported filing row; may be amended. Do not sum filings blindly. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References:	S Sale (market/private)Common Stock · Non-derivative	2,644D	89.98	Direct	Form 4 ↗0001225208-26-007377
2026-08-26Filed 2026-08-26	Chopra DaveenOfficer · CVP, TMTT, Surgical & IHFM Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This transaction was executed in multiple trades at prices ranging from $91.660 to $91.975. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 This transaction was executed in multiple trades at prices ranging from $90.645 to $91.640. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References:	M Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative	31,800D	0	Direct	Form 4 ↗0001225208-26-007335
2026-08-26Filed 2026-08-26	Chopra DaveenOfficer · CVP, TMTT, Surgical & IHFM Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This transaction was executed in multiple trades at prices ranging from $91.660 to $91.975. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 This transaction was executed in multiple trades at prices ranging from $90.645 to $91.640. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F2	S Sale (market/private)Common Stock · Non-derivative	30,646D	90.9922	Direct	Form 4 ↗0001225208-26-007335
2026-08-26Filed 2026-08-26	Chopra DaveenOfficer · CVP, TMTT, Surgical & IHFM Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This transaction was executed in multiple trades at prices ranging from $91.660 to $91.975. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 This transaction was executed in multiple trades at prices ranging from $90.645 to $91.640. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1	S Sale (market/private)Common Stock · Non-derivative	1,154D	91.7614	Direct	Form 4 ↗0001225208-26-007335

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.